P215 Endoscopic remission (Mayo score 0 rather than score 1) predicts long-term clinical remission in ulcerative colitis

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

“…Based on the literature, a subscore of 0 or 1 should be considered as endoscopic remission ( 130 ) (CEBM 1a). Experts agreed that a Mayo endoscopic subscore of 0 is the optimal target, although there is insuffi cient information to recommend this target for all patients, and a subscore of 1 should be a minimum target ( 144,145 ). In the Active Ulcerative Colitis Trials-1 and -2 of infl iximab in patients with moderate-to-severe UC, 25% of patients had achieved a Mayo endoscopy subscore of 0 by week 8, with 61% achieving a score of 0 or 1 ( 50 ).…”

Assessing Severity of Disease in Patients with Ulcerative Colitis

“…Importantly, despite making the stated goals of treatment to include an endoscopic assessment, the committee noted that there was a lack of direct evidence linking the achievement of endoscopic targets in UC to improved outcomes, with most of the evidence coming from epidemiologic studies or being inferred from clinical trial data with heterogeneous end points. 67 , 68 , 69 , 70 Since then, mounting evidence points to the superior predictive ability of the UCEIS scoring system compared with the Mayo endoscopic subscore. In addition, several barriers to the adoption of a treat-to-target strategy continue to limit its widespread adoption.…”